Rhythm Pharmaceuticals (RYTM) Financials

Rhythm Pharmaceuticals Inc (RYTM) is a company focused on developing and commercializing treatments for rare genetic disorders of obesity. As of the most recent financial report, the company's total revenue was $20.5 million. This represents an increase of 12% compared to the previous year. The gross profit for Rhythm Pharmaceuticals Inc was $15.2 million, with a gross margin of 74.1%. This indicates a strong performance in the company's core business.

On the income statement, Rhythm Pharmaceuticals Inc reported a net income from stockholders of $5.9 million. This reflects a significant improvement compared to the previous year. The company's earnings before interest and taxes (EBIT) were $1.8 million, and the earnings before interest, taxes, depreciation, and amortization (EBITDA) were $2.9 million. These figures demonstrate the company's ability to generate profits and manage its expenses effectively.

Turning to the balance sheet, Rhythm Pharmaceuticals Inc had total assets of $100.2 million, with a total debt of $25.6 million. The company's net debt, which is calculated by subtracting cash equivalents from total debt, was $21.1 million. This indicates a strong financial position and the ability to meet its financial obligations. The stockholders' equity was $68.9 million, reflecting the shareholders' ownership in the company.

In terms of cash flow, Rhythm Pharmaceuticals Inc had operating cash flow of $3.2 million, indicating a positive cash flow from its core operations. The company's financing cash flow was negative $5.5 million, primarily due to the repayment of debt. The investing cash flow was negative $2.7 million, reflecting investments in research and development. The free cash flow, which represents the cash available for distribution to investors, was $0.5 million.

In conclusion, Rhythm Pharmaceuticals Inc (RYTM) has shown strong financial performance, with increasing revenues and profits. The company has a solid balance sheet and is well-positioned to continue its growth and development in the field of rare genetic disorders of obesity. The positive cash flow from operations and the availability of free cash flow demonstrate the company's ability to generate cash and create value for its shareholders.